

Market Announcement

24 June 2026

Recce Pharmaceuticals Ltd (ASX: RCE) – Trading Halt

Trading in the securities of Recce Pharmaceuticals Ltd ('RCE') will be halted at the request of RCE, pending the release of an announcement by RCE.

Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of:

- the commencement of normal trading on Friday, 26 June 2026; or
- the release of the announcement to the market.

RCE's request for a trading halt is attached below for the information of the market.

Issued by

ASX Compliance

24 June 2026

Monique Burley
Adviser, Listing Compliance (Perth)
Level 40 Central Park
152 - 158 St Georges Terrace
Perth WA 6000

By email: tradinghaltsperth@asx.com.au

Dear Monique,

Recce Pharmaceuticals Ltd (ASX:RCE) – Trading halt request

Pursuant to ASX Listing Rule 17.1, Recce Pharmaceuticals Ltd (ASX:RCE) (the **Company**) requests a trading halt of the Company's securities pending the release of an announcement relating to a proposed equity capital raise.

The Company requests that the trading halt be effective immediately and remain in place until the earlier of the commencement of normal trading on Friday, 26 June 2026 or the release of an announcement by the Company in relation to a capital raising.

The Company is not aware of any reason why the trading halt should not be granted nor any other information necessary to inform the market about the trading halt.

For further information, please contact:

Maggie Niewidok
Company Secretary
company.secretary@recce.com.au

This announcement has been approved for release by Recce Pharmaceuticals Board.



ASX: RCE, FSE: R9Q

Head Office: Level 15, 1 Farrer Place, Governor Macquarie Tower, SYDNEY NSW 2000 T +61 (2) 9000 1907

R&D Centre - Perth: Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 T +61 (8) 9362 9860

Washington Office: 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA